{"filing":{"accession_number":"0001193125-26-260640","cik":"0001789972","ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"cgem-20260606.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/cgem-20260606.htm"},"events":[{"id":6169,"run_id":5417,"accession_number":"0001193125-26-260640","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Cullinan Therapeutics announced initial Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients from the OUTRACE trials, showing clinical activity with 71% of SLE patients achieving ≥4-point hSLEDAI reduction and 71% of RA patients demonstrating disease activity improvement, along with B cell depletion biomarker results. The data was presented at EULAR, a major rheumatology conference, and materially affects investor assessment of the company's pipeline development trajectory.","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5032,"accession_number":"0001193125-26-260640","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces initial Phase 1 clinical trial data for CLN-978 in RA and SLE patients being presented at EULAR, a major rheumatology conference. While this is clinical progress rather than a traditional earnings release or executive event, the presentation of Phase 1 data for a therapeutic candidate is material to investors assessing the company's pipeline and development trajectory. However, the event does not fit neatly into the more specific categories (earnings_release, exec_departure, ma_activity, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:33:09.253191+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5033,"accession_number":"0001193125-26-260640","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses initial Phase 1 clinical data from the OUTRACE trials for CLN-978 in SLE and RA patients, showing clinical activity (71% of SLE patients achieved ≥4-point hSLEDAI reduction; 71% of RA patients showed disease activity improvement) and B cell depletion biomarker results. While this is clinical trial progress rather than a discrete event like earnings, M\u0026A, or executive change, the interim efficacy and safety data from an early-stage therapeutic program would materially affect investor assessment of the company's pipeline prospects. This does not fit neatly into the more specific event categories, making \"other_material\" the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:33:09.253191+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5032,"accession_number":"0001193125-26-260640","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces initial Phase 1 clinical trial data for CLN-978 in RA and SLE patients being presented at EULAR, a major rheumatology conference. While this is clinical progress rather than a traditional earnings release or executive event, the presentation of Phase 1 data for a therapeutic candidate is material to investors assessing the company's pipeline and development trajectory. However, the event does not fit neatly into the more specific categories (earnings_release, exec_departure, ma_activity, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:33:09.253191+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-06-08"},{"id":5033,"accession_number":"0001193125-26-260640","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses initial Phase 1 clinical data from the OUTRACE trials for CLN-978 in SLE and RA patients, showing clinical activity (71% of SLE patients achieved ≥4-point hSLEDAI reduction; 71% of RA patients showed disease activity improvement) and B cell depletion biomarker results. While this is clinical trial progress rather than a discrete event like earnings, M\u0026A, or executive change, the interim efficacy and safety data from an early-stage therapeutic program would materially affect investor assessment of the company's pipeline prospects. This does not fit neatly into the more specific event categories, making \"other_material\" the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T10:33:09.253191+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-06-08"}]}